KDC-MN-056 – Kodiac biolabs

Plain-language summaryIntrigue 40 / 100

CX-614 is another benzoxazine ampakine in the Cortex series. Investigated in early clinical trials for cognitive impairment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

42/100

Potent AMPA probe with real bench utility but no translational path and a stalled class

CX-614 is a benzoxazine ampakine out of the Cortex Pharmaceuticals program that ran through the late 1990s and 2000s alongside CX-516 and CX-546. The compound is legitimately interesting as a probe: its roughly 100-fold potency advantage over CX-516 in AMPA receptor potentiation assays isn’t marketing noise, it shows up consistently in comparative cellular work. If you’re running BDNF induction studies and want pharmacological control over AMPA throughput without saturating concentrations, CX-614 is a real tool.

The BDNF upregulation story is the most compelling part of the science here. Chronic ampakine treatment drives hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation. This is a legitimate model for studying neurotrophin-mediated synaptic plasticity and it’s been used by multiple independent groups, not just the originating program. That matters. Replication outside Cortex gives the bench utility real credibility and separates CX-614 from single-lab-only probe compounds.

Here’s the thing though: the ampakine class as a therapeutic direction has largely stalled. CX-516 had a small clinical footprint and the results were underwhelming. Seizure risk and excitotoxicity concerns have shadowed every high-potency member of the class. CX-614’s potency, which is an asset on the bench, is a liability from a translational standpoint. That 100-fold number doesnt come with a 100-fold therapeutic window, and there’s no sponsor currently pushing a benzoxazine ampakine through a pipeline.

We dont see a strong path to clinical relevance for CX-614 specifically. The novel angle, AMPA-driven BDNF induction as a tractable route to synaptic plasticity enhancement, remains interesting theoretically, but the pharmacological levers available today include BDNF mimetics, TrkB agonists, and ketamine’s downstream BDNF release mechanism, all of which generate stronger translational signals with more current evidence behind them. The class simply hasn’t rehabilitated itself with more recent data, and CX-614 inherits that problem.

What CX-614 does well is narrow but real: it’s a high-potency probe for dissecting AMPA receptor contributions to BDNF signaling in controlled in vitro and rodent systems. If thats the question you’re asking, honestly, it earns a spot in the toolkit. If you’re looking for a compound that carries a compelling story toward clinical translation or opens a genuinely new mechanistic frontier, there are better candidates right now. The score reflects a compound that occupies a legitimate but limited niche: not junk, not boring, but not the compound you build a program around in 2026.

Novelty: 38
Mechanism promise: 48
In-category differentiation: 45
Evidence quality: 42
Translational signal: 22
Research bench value: 62

Rationale CX-614 earns its place as a legitimate preclinical probe for AMPA-mediated BDNF induction, with multi-lab use validating the bench utility score; however, the ampakine class has largely failed to translate and CX-614 itself has never entered human trials, keeping translational and novelty scores low and pulling the overall to the low 40s.

Benzoxazine ampakine

A potent benzoxazine ampakine with research applications in BDNF upregulation and synaptic plasticity studies.

Abstract

CX-614 (2H,3H,6aH-pyrrolidino-[2,1-3′,2′]1,3-oxazino-[6′,5′-5,4]benzo[e]1,4-dioxan-10-one; CAS 215923-55-0; molecular formula C16H17NO4; molecular weight 287.32) is a potent benzoxazine-class ampakine developed at Cortex Pharmaceuticals as part of the same program that produced CX-516 and CX-546. CX-614 shows substantially higher AMPA potentiation potency than CX-516 in cellular assays (approximately 100-fold greater per molecule). The compound has been used extensively as a research probe for BDNF upregulation studies; chronic ampakine treatment elevates hippocampal BDNF expression through transcriptional mechanisms downstream of AMPA potentiation, providing a pharmacological model for neurotrophin-mediated synaptic plasticity. CX-614 has not been advanced to human clinical trials. The compound is sold as a research chemical with limited availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-056Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-056

CX-614

Abstract

Read the full monograph